Japanese fans staying behind in the stadium to clean their sector after the 2-2 draw against the Netherlands in Dallas. This is a Japanese tradition has gone viral at numerous previous World Cups. 🇺🇸🇯🇵

A pragmatic EHR‐derived model accurately predicts 30‐day periprocedural ischemic stroke across diverse procedures and is available as a web‐based calculator to support counseling and targeted prevention. High risk = suggest stroke consult. 👏 @ShuLiqi ahajournals.org/doi/10.1161/…

JUST IN: Florida hospital reveals Palantir software has cut sepsis deaths by more than half since it was installed.

#STROKE: Among >500,000 Medicare patients from GWTG-Stroke, rural patients had ⬇️ inpatient rehab use, ⬆️ skilled nursing facility discharge, and less 1-year home-time despite similar overall mortality. ahajournals.org/doi/full/10.…

"If you hate a person, you hate something in him that is part yourself. What isn’t part ourselves doesn’t disturb us." — Hermann Hesse "Everything that irritates us about others can lead us to an understanding of ourselves." — Carl Jung 3 different perspectives, one concept.

We have just updated our RCVS differential diagnosis checklist with this paper neurochecklists.com/explore/…

ICYMI: The May #Stroke Cover Figure, entitled “The Shadow of Diagnosis,” visually reflects the emotional burden of anxiety and depression following aneurysm diagnosis. ahajournals.org/doi/10.1161/…

1/5 I'm a cardiologist. I have spent twenty years watching cholesterol destroy arteries, trigger heart attacks, and kill people I care about. Today, Eli Lilly presented data that may begin to end that era. VERVE-102. A single infusion. One dose. It uses base editing to permanently turn off the PCSK9 gene in your liver. Presented today at the European Atherosclerosis Society Congress: 88% reduction in PCSK9. 62% reduction in LDL cholesterol. Sustained up to 18 months. No treatment-related serious adverse events. One infusion. Not daily pills you forget to take. Not monthly injections. One dose — and your cholesterol may stay low for the rest of your life.

$50 a month for GLP-1 drugs. That’s what Medicare will charge for Wegovy or Zepbound starting July 1. The retail price without insurance is over $1,000. CMS confirmed it this week. The Medicare GLP-1 Bridge program caps the copay at $50 flat, regardless of which benefit phase you’re in, regardless of what the drug actually costs. Eligible if your BMI is 27 with a comorbidity, or 35 . That’s tens of millions of Americans. The conventional wisdom was that GLP-1s were a rich person’s drug. Too expensive for Medicare patients, too politically fraught to subsidize, too new to cover at scale. Every part of that is now wrong. Drug prices are rising almost everywhere else this year. Medicare just moved in the opposite direction on the most-discussed drug class in the world. The era of GLP-1s being out of reach for older Americans is over.

🧠🚨 @US_FDA grants Priority Review to Bayer’s investigational FXIa inhibitor #asundexian for secondary stroke prevention after non-cardioembolic ischemic stroke/TIA Phase 3️⃣ data showed reduced recurrent stroke risk without increased major bleeding 📉💊 Read more 👉 hubs.li/Q04hhGMX0 #Stroke #Neurology #FDA #FDANews

In IIH, dural venous sinus stenting is not only associated with reduced reprocedure rates and better symptom control, but also with a lower risk of new neurocognitive deficits compared with CSF shunting. By @HAlvinChenNeuro @Dheeraj_NIS doi.org/10.3174/ajnr.A9407

GLP-1RA use was associated not only w/ lower intracranial aneurysm rupture risk, but also w/ attenuated rupture severity & less severe outcomes among patients w/ ruptured aneurysms, suggesting potential vascular stabilizing effects. By @HAlvinChenNeuro doi.org/10.1161/STROKEAHA.12…

Among adults with early #ParkinsonDisease, fixed-dose tavapadon (5 or 15 mg once daily) improved motor function over 26 weeks versus placebo, with most adverse events mild or moderate in severity. ja.ma/4dw1D35

Vaccine Anti vaccine research research

In this study led by @EkaBakradze1: 1 in 6 patients ultimately diagnosed w cervical artery dissection had a visit within 30 days for neurological symptoms but were not diagnosed at the time. As a reference, in aortic dissection it’s 1 in 3! @StrokeAHA_ASA ahajournals.org/doi/10.1161/…

lol

🫀⚠️ SCOT-HEART changed cardiology with one simple idea: 👉 First scan. Then treat. This is going to generate some hitching to some colleagues within the community 😁. Sorry about that. And 10 years later… the message is even more disruptive. For decades, we built cardiology around: 👉 ischemia 👉 stress tests 👉 flow limitation Find ischemia. Open arteries. Simple. Except… it didn’t reduce hard events consistently. SCOT-HEART helped expose the problem: 👉 Atherosclerosis—not ischemia—is the real disease. At 10 years: 👉 coronary CT guidance reduced: - coronary death - non-fatal MI despite: ❌ NO increase in revascularization Let that sink in. Patients did better NOT because we opened more arteries. They did better because: 👉 we identified plaque 👉 intensified prevention 👉 treated biology earlier The most important number may not be stenosis anymore. It may be: 👉 total plaque burden 👉 plaque phenotype 👉 lipid-rich disease 👉 adverse plaque features The paper says it clearly: Patients with: ⚠️ low-attenuation plaque ⚠️ positive remodeling had dramatically higher event rates. This is the paradigm shift From: ❌ ischemia-centered cardiology To: 👉 plaque-centered prevention And the implications are enormous. Because suddenly: 👉 non-obstructive CAD matters 👉 “normal” stress tests become insufficient 👉 anatomy alone becomes incomplete Even more interesting The next frontier is already here: ⚡ Photon Counting CT ⚡ AI-driven plaque analysis ⚡ Radiomics ⚡ Quantitative phenotyping My take SCOT-HEART did not simply validate coronary CT. It challenged the entire logic of modern cardiology. We used to ask: 👉 “Is this lesion ischemic?” Now the real question is: 👉 “How biologically dangerous is this patient?” Bottom line The future is not: 👉 detect stenosis 👉 react late It is: 👉 detect atherosclerosis early 👉 personalize prevention aggressively ⚡ Because myocardial infarction often starts long before ischemia appears. #SCOTHEART #CCTA #Cardiology #Atherosclerosis #PlaqueImaging #Prevention #PhotonCounting #AI #PrecisionMedicine

🧵 THREAD: Heart failure kills 50% of patients within 5 years of diagnosis. But modern GDMT can add 6 years of life. Here's the complete evidence hierarchy — ARR, RR, NNT, years gained, combination rankings & ICER ranked best to worst.

Master oncology quiz question What do melanoma, hairy cell leukemia, and Erdheim Chester disease have in common?